Latin America Pharmaceutical Drug Market

Brazil’s drug makers billed BRL 182.8 billion in 2025, 13.7% more than in 2024, while the number of packs they sold rose only 3.72% to 6.30 billion, according to the CMED statistical yearbook published by the National Health Surveillance Agency (Anvisa) in 2026, and on 30 March 2026 the price regulator capped 2026 list-price rises at 1.13% to 3.81%. Latin America’s largest market is growing on what it sells, not on what it charges for old medicines. The Latin America pharmaceutical drug market covers the finished prescription and over-the-counter medicines sold to patients, pharmacies, hospitals and public buyers in Brazil, Mexico, Argentina, Colombia, Chile, Peru and the rest of Latin America, valued at manufacturer invoice prices, across branded small molecules, generics, branded biologics, biosimilars and over-the-counter (OTC) medicines. Douglas Insights sizes it at USD 91.9 billion in 2025, from 330 billion defined daily doses (DDDs) at an average USD 0.278 a dose, and at USD 183 billion in 2035, a revenue CAGR (compound annual growth rate) of 7.15%. The study sits in our pharmaceuticals coverage, is the Latin America row of our worldwide Pharmaceutical Drug Market report, and every figure follows the Douglas Insights research methodology.

Which Latin America pharmaceutical drug segments carry the value: branded small molecules, generics or biologics?

Branded small molecules carry the most Latin America pharmaceutical drug value, 36.0% of 2025, USD 33.1 billion, because branded tablets still dominate private pharmacies. Biosimilars grow fastest, 14.0% a year, from USD 2.76 billion to USD 10.2 billion.

Branded small molecules, USD 33.1 billion, lead because Latin American patients pay for much of their own medicine at the pharmacy counter and doctors prescribe by brand, including the branded copies that Brazil calls similares and Mexico and Argentina sell under company names. They grow 5.60% a year, the slowest prescription line, as patents expire and public buyers switch to cheaper versions. Generics, USD 24.8 billion, grow 7.00% a year on volume: Brazil’s registered generics alone billed BRL 25.2 billion in 2025, 13.8% of its market, the CMED yearbook shows.

Branded biologics, USD 20.2 billion, grow 9.00% a year because cancer antibodies, immunology injectables and GLP-1 pens cost USD 8 to USD 30 a daily dose and public health systems in Brazil, Mexico and Colombia keep adding them to their lists; biological products already billed BRL 57.0 billion in Brazil in 2025, 31.2% of the total. Biosimilars, USD 2.76 billion, grow fastest, 14.0% a year, because Brazil’s public partnerships and Mexico’s consolidated tenders switch quickly to copies once an antibody loses protection. OTC medicines, USD 11.0 billion, grow 6.00% as pharmacy chains widen self-care. Product-type values for 2035 sum to USD 184 billion, 0.24% above the headline. How Europe’s mix compares is shown in our Europe Pharmaceutical Drug Market report.

What drives Latin America pharmaceutical drug spending per dose up 5.77% a year to 2035?

Latin America pharmaceutical drug spending per daily dose rises 5.77% a year, from USD 0.278 in 2025 to about USD 0.488 in 2035, because specialty launches, inflation-linked price updates, GLP-1 drugs and mix add 7.00 points before restraints.

Daily doses grow 1.30% a year, from 330 billion to about 375 billion, as the region ages and public programmes widen access. Four drivers make up the gross price-and-mix leg.

Oncology and immunology launches: 2.60 points

New specialty medicines add 2.60 points. Each new cancer or immunology drug replaces older, cheaper therapy at a much higher price per dose, and Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS) granted 312 medicine registrations and authorised 183 clinical trials in 2025, its year-end release of 31 December 2025 states.

Inflation-linked price updates: 2.20 points

Price updates add 2.20 points. Brazil lets list prices rise once a year by a formula tied to inflation, and Argentina’s prices follow the peso: Genomma Lab’s Argentine sales rose 39.7% in local currency in 2025 but fell 20.1% in Mexican pesos after a 42% depreciation, its results of 25 February 2026 show.

GLP-1 drugs for diabetes and obesity: 1.40 points

Diabetes and obesity add 1.40 points. Semaglutide pens cost many times the metformin they partly replace; Brazil’s semaglutide patent expired on 20 March 2026 and Anvisa registered EMS’s synthetic semaglutide pen Ozivy on 26 May 2026, the agency said, so cheaper copies widen use rather than end it.

Mix toward specialty care: 0.80 points

Mix adds 0.80 points. Brazil’s revenue per pack rose 9.65% in 2025 while pack volume rose 3.72%, our calculation from the CMED yearbook, as dearer biologics took share. The four contributions, 2.60 + 2.20 + 1.40 + 0.80, give 7.00 points.

What holds back Latin America pharmaceutical drug prices: copies, public tenders or currencies?

Three headwinds remove 1.23 points from Latin America pharmaceutical drug price growth, leaving 5.77% a year: generic and biosimilar copies take 0.55 points, public price caps and tenders 0.48 points and currency weakness 0.20 points.

Copies are the largest brake. When Brazil’s semaglutide patent ended, Anvisa registered EMS’s pen within ten weeks, and copies of antibodies and tablets cut the price per dose by 30% to 70% once they reach public lists, so Douglas Insights removes 0.55 points. Public buyers remove 0.48 points: Brazil’s Drug Market Regulation Chamber (CMED) set 2026 maximum rises of 3.81%, 2.47% and 1.13% for its three competition levels from 31 March 2026, under Resolution CM-CMED No. 4 of 30 March 2026, and Mexico buys most public-sector medicines through consolidated national tenders that reward the lowest bid.

Currencies remove 0.20 points. Our forecast is in U.S. dollars, and in the Argentine and Colombian markets local price rises can lag depreciation for a year or more, as Genomma Lab’s 42% Argentine translation loss shows. Multinationals respond by launching later in smaller markets or by licensing brands to local firms such as Eurofarma, EMS and Hypera.

Where in Latin America is pharmaceutical drug money spent, and which country grows fastest?

Brazil spends the most on pharmaceutical drugs in Latin America, USD 32.8 billion or 35.6% of 2025, from Anvisa’s BRL 182.8 billion. Argentina grows fastest, 7.90% a year to USD 23.6 billion by 2035, with Brazil next at 7.60%.

Brazil leads because it has the region’s largest population, about 230 drug makers and a public system that buys and dispenses medicines nationwide; the Anvisa total, converted at BRL 5.58 per U.S. dollar, gives USD 32.8 billion. It grows 7.60% a year as biologics and GLP-1 copies widen use. Mexico, USD 20.2 billion, grows 6.60%, slower than Brazil, because consolidated public tenders hold down prices and its private market is more price-sensitive; COFEPRIS’s faster approvals are the main upside.

Argentina, USD 11.0 billion, grows fastest, 7.90% a year in dollars, because its prices are recovering in hard-currency terms after the devaluation and because local makers such as Roemmers and Elea hold strong branded portfolios at home. Colombia, USD 7.35 billion, grows 7.30% on wider insurer coverage; Peru, USD 3.22 billion, 7.40%; Chile, USD 5.05 billion, 6.20%, the slowest because its market is already mature. The rest of Latin America, from Ecuador and Central America to the Caribbean, holds USD 12.3 billion. Country values for 2035 sum to USD 185 billion, 0.88% above the headline; in the data table the row labelled Global holds the Latin America total. The same build for other regions is in our U.S. Pharmaceutical Drug Market and Asia Pacific Pharmaceutical Drug Market reports.

Which companies dominate Latin America pharmaceutical drug sales, and how much do local makers hold?

EMS is the largest Latin America pharmaceutical drug seller, with about 3.0% of 2025 value, USD 2.76 billion, a Douglas Insights estimate. The top three, EMS, Sanofi and Novartis, hold about 7.9%; local makers hold far more than in Europe.

All shares are Douglas Insights estimates because companies report Latin American sales in different groupings or not at all. Hypera’s net revenue was BRL 7.70 billion in 2025, up 3.4%, it said on 12 March 2026, which converts to USD 1.38 billion. Genomma Lab sold MXN 17.5 billion worldwide in 2025, down 5.7%, with Latin America outside Argentina up 7.4% on Brazil, Chile, Central America and the Andean countries, its full-year report states. Local scale matters in Latin America more than anywhere else: a maker with a factory, a sales force for pharmacy chains and registrations in Brazil can launch a copy on the day a patent ends, as EMS did with semaglutide, while multinationals win in hospital specialty medicines and public tenders for patented drugs.

How much does a daily dose of medicine cost in Latin America, and why is it about a third of Europe’s?

A daily dose of medicine cost an average USD 0.278 in Latin America in 2025, Douglas Insights estimates, about 36% of Europe’s USD 0.772, from USD 0.05 for a generic tablet to over USD 20 for a branded biologic.

The bands are Douglas Insights estimates from national price lists and company disclosures. The gap with Europe is about income and mix: generics and similares supply most of Latin America’s doses, and biologics reach fewer patients. Brazil’s average revenue per pack was BRL 29.02 in 2025, up from BRL 26.47 in 2024, our calculation from the CMED yearbook, a 9.65% rise against list-price caps that stayed below inflation. The regional average reaches about USD 0.295 a dose in 2026 and USD 0.488 in 2035, still below Europe’s level today.

Which rules shape Latin America pharmaceutical drug sales: CMED price caps, COFEPRIS reform or Farmácia Popular?

Three rule sets shape Latin America pharmaceutical drug sales most: Brazil’s CMED annual price caps, Mexico’s COFEPRIS regulatory reform and consolidated purchasing, and public access programmes such as Brazil’s Farmácia Popular.

Brazil’s CMED sets a ceiling price for every registered medicine and allows one rise a year. For 2026 the ceilings rose by at most 3.81%, 2.47% or 1.13% depending on how much competition a medicine faces, effective 31 March 2026, under Resolution CM-CMED No. 4; a new medicine such as EMS’s semaglutide pen can be sold only after CMED approves its maximum price, Anvisa noted. The rule caps existing prices but not mix, which is why value outgrows the caps.

In Mexico, COFEPRIS cut its procedures from 287 to 106 through 11 agreements published in the Diario Oficial de la Federación in 2025 and extended sanitary registrations from 5 to 10 years, its year-end release says, and it is seeking World Health Organization Listed Authority status. Brazil’s Farmácia Popular gives free medicines for hypertension, diabetes and asthma through private pharmacies, adding doses rather than price; that is why public access sits in the 1.30% volume leg.

What if public tenders tighten: where does Latin America pharmaceutical drug spending land in 2035?

The Latin America pharmaceutical drug market ends 2035 between USD 153 billion and USD 216 billion across our three cases, around a base of USD 183 billion. Public price discipline and currency paths set most of the spread.

In the slower case Mexico and Colombia push more spending into lowest-bid tenders, Brazil’s caps stay near 1% and the Argentine and Colombian pesos weaken again. In the faster case biologics and GLP-1 copies reach public lists quickly and currencies hold. One extra point of yearly price growth adds USD 18.1 billion to 2035 Latin America pharmaceutical drug value; one point less removes USD 16.6 billion.

The 7.15% base rate sits above the 5.71% we use for the worldwide pharmaceutical drug market and the 4.43% for Europe, because Latin America still adds patients and specialty therapies from a lower base, and below the 8.21% for the Middle East and Africa.

Douglas Exclusive: the Brazil Pack-Value Ledger

The Brazil Pack-Value Ledger is a Douglas Insights calculation, not an official statistic, from the CMED yearbook and two 2026 Anvisa decisions, separating Brazil’s 2025 value growth into packs sold and value per pack.

The finding, a Douglas Insights estimate: at most 3.81 points of Brazil’s 9.65% value-per-pack gain can come from list-price rises under the 2026 caps, so at least 5.84 points come from patients moving to dearer medicines, mostly biologics. That is why we put inflation-linked price updates at only 2.20 points of the regional 7.00-point gross price leg and mix and launches at 3.40 points: in Latin America, regulators control what a medicine costs, not which medicines doctors prescribe.

How does the methodology turn 330 billion daily doses into USD 91.9 billion of Latin America pharmaceutical drug sales?

Our methodology multiplies 330 billion defined daily doses sold in Latin America in 2025 by an average USD 0.278 a dose to reach USD 91.9 billion. Doses come from seven country builds; Brazil is anchored on Anvisa data.

The model covers 7 countries or sub-regions, 5 product types and 3 channels, and uses 96 data points, 19 sourced and 77 modelled. Arithmetic: 330 billion doses x USD 0.2785 = USD 91.9 billion; USD 91.9 billion x (1.0130 x 1.0577)^10 = USD 183 billion. Doses reach 334 billion in 2026 and 375 billion in 2035; price per dose reaches USD 0.295 in 2026. BRL figures convert at BRL 5.58 per U.S. dollar.

Two cross-checks agree. First, the Latin America row of our worldwide Pharmaceutical Drug Market model is USD 91.9 billion in 2025 and USD 183 billion in 2035, 5.14% of the USD 1.79 trillion world total. Second, Brazil’s USD 32.8 billion, built from the official BRL 182.8 billion, is 35.6% of the regional total, consistent with Brazil’s place as the region’s largest market. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Anvisa / CMED Anuário Estatístico do Mercado Farmacêutico 2025 (2026)
2. Anvisa / CMED Resolução CM-CMED nº 4, de 30 de março de 2026 (2026)
3. Anvisa Anvisa approves the first synthetic semaglutide pen for diabetes (2026)
4. COFEPRIS COFEPRIS consolida en 2025 un sistema regulatorio más ágil (2025)
5. Genomma Lab Internacional Genomma Lab fourth quarter and full year 2025 results (2026)

What counts in the Latin America pharmaceutical drug market, and what is excluded?

The Latin America pharmaceutical drug market counts finished prescription and OTC medicines sold in Latin America at manufacturer invoice prices. Pharmacy and wholesale margins, sales taxes, active ingredients sold to other makers, veterinary medicines and medical devices are excluded.

The by-product-type split covers branded small molecules, generics, branded biologics, biosimilars and OTC medicines; the by-channel split covers retail pharmacy, hospital and public institutional supply, and online pharmacy; the by-country split covers Brazil, Mexico, Argentina, Colombia, Chile, Peru and the rest of Latin America.